PRESCINTO-TECHNOLOGIES
22.11.2022 07:01:42 CET | Business Wire | Press release
Prescinto Technologies (“Prescinto”), a leading global clean energy asset performance management (APM) SaaS platform, and SunSolarWind IKE (“SunSolarWind”), a Thessaloniki-based wind and solar energy project developer with a rapidly growing portfolio of more than 100 projects across Greece, today announced a partnership in which Prescinto will apply its world-class AI-powered APM solution to monitor, analyze, optimize the performance of 70 MW of SunSolarWind’s solar assets. This alliance will streamline operations and maintenance for SunSolarWind and improve their solar asset generation by providing accurate, real-time data and actionable insights. The deal also marks Prescinto’s entry into the European market following the announcement of its recent entry into the North American market.
As one of the fastest-growing companies in Greece, SunSolarWind is a leader in renewable energy development and provides complete packages for the construction and management of wind and photovoltaic energy projects on behalf of its customers and partners. Using Prescinto’s proprietary AI-powered software, the company will have access to advanced monitoring technology and pre-trained data models to identify and categorize underperformance in real time. The platform will provide a single point of verification for SunSolarWind’s solar plant data, extracting up-to-the-minute insights and efficiently managing the field service team’s daily operations using Prescinto’s Monitor, Analyze, and Operate product modules. These solutions leverage data-driven intelligence to enable informed asset management and maximize the value of SunSolarWind clean energy assets.
In an increasingly competitive energy market, digital technology plays a critical role in optimizing operations and performance. SunSolarWind chose Prescinto as their digital transformation partner after a stringent evaluation of multiple other solutions. Additionally, Prescinto’s APM software is uniquely designed to efficiently adapt to the client's needs and is tailored to SunSolarWind’s specific requirements.
“Our team has worked closely with SunSolarWind to understand their bottlenecks and implement the appropriate solutions to enhance energy generation and streamline their operations,” said Puneet Singh Jaggi, founder and CEO of Prescinto. “As our first of many major partnerships to come in the European market, we are excited to be a part of SunSolarWind’s digital transformation journey and help them harness the full potential of their clean energy assets.”
“With our exponential growth in managed assets, the SunSolarWind team can now focus more on improving asset performance with a considerable reduction in time and effort,” says Konstantinos Fountas, Partner at SunSolarWind. “The advanced analytics in Prescinto’s platform helps to identify and plan remedial action and reduce equipment downtimes. For a company like ours, Prescinto’s solution, and their Computerized Maintenance Management System in particular, is a boon.”
With its expansion into the European market with its first Greece-based client, Prescinto is poised for further growth and progress toward its goal of being the asset management platform of choice for renewable energy projects, globally.
About Prescinto Technologies
Prescinto Technologies is a leading global clean energy asset performance management SaaS platform for solar, wind, and energy storage, purpose-built by industry experts to improve asset generation and accelerate the clean energy transition. Prescinto provides real-time insights, analytics, and automation support for optimizing renewable energy asset performance. With a veteran team of industry experts and a portfolio of over 13 GW across 14 countries, Prescinto is the trusted partner for global clients working toward the clean energy transition. For more info, visit www.prescinto.ai.
About SunSolarWind
Sun Solar Wind Ike is a rapidly growing company in the field of environmental energy applications, comprised of well-trained and certified staff. The company offers complete packages for the construction and management of photovoltaic systems and energy projects on behalf of either its customers or its partners – installers. With more than 70MWp of assets under management in Greece, SunSolarWind is among Greece's fastest-growing renewable energy companies. For more info, visit www.sunsolarwind.gr.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom